netFormulary
 Report : Medicines with links to NICE 23/10/2017 23:39:53

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA 373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Formulary NICE TA 195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abiraterone Actetate 08.03.04.02 Formulary NICE TA 259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Abiraterone Actetate 08.03.04.02 Formulary NICE TA 387 - Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 13.05.03 Formulary NICE TA 199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 13.05.03 Formulary NICE TA 392 - Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Formulary NICE TA 455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 13.05.03 Formulary NICE TA 146 - Adalimumab for the treatment of adults with psoriasis
Adalimumab 10.01.03 Formulary NICE TA 195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Adalimumab 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA 373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA 383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adefovir Dipivoxil 05.03.03 Non Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Afatinib 08.01.05 Formulary NICE TA 310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA 408 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA 294 - Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA 305 - Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA 346 - Aflibercept for treating diabetic macular oedema
Agomelatine 04.03.04 Non Formulary NICE TA 231: Agomelatine for the treatment of major depressive disorders (terminated appraisal)
Alemtuzumab 08.02.03 Formulary NICE TA 312 - Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Formulary NICE TA 161 - Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Alendronic Acid 06.06.02 Formulary NICE TA 161 - Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Alirocumab 02.14 Restricted Use NICE TA 393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Amitriptyline 04.07.03 Formulary NICE clinical guideline 173 - Neuropathic pain in adults: pharmacological management in non-specialist settings
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TAG156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA 341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA 275 - Apixaban for preventingstroke and systemic embolism in people with nonvalvularatrial fibrillation
Apixaban 02.08.02 Formulary NICE TA 245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 13.05.03 Restricted Use NICE TA 419 - Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Restricted Use NICE TA 292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Axitinib 08.01.05 Formulary NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Formulary NICE 399 - Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Belimumab 10.01.03 Formulary NICE TA 397 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216 - Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bevacizumab 08.01.05 Formulary NICE TA 214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.05 Formulary NICE TA 263: - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bivalirudin 02.08.01 Formulary NICE TA230: Bivalirudin for the treatment of STEMI, 2011
Boceprevir 05.03.03 Formulary NICE TA 253 - Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Formulary NICE TA 370 - Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA 228 - Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA 311 - Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 08.01.05 Formulary NICE TA 129 - Bortezomib monotherapy for relapsed multiple myeloma
Bosutinib 08.01.05 Formulary NICE TA 401 - Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.09.03 Formulary NICE TA 260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum Toxin Type A 04.09.03 Formulary NICE TA 260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum Toxin Type A 04.09.03 Formulary NICE TA 260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Formulary NICE TA - 446 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Buprenorphine 04.07.02 Formulary NICE TA 114 - Methadone and buprenorphine for the management of opioid dependence
Buprenorphine 04.07.02 Formulary NICE TA 114 - Methadone and buprenorphine for the management of opioid dependence
Buprenorphine 04.07.02 Formulary NICE TA 114 - Methadone and buprenorphine for the management of opioid dependence
Cabazitaxel 08.01.05 Restricted Use NICE TA 391 - Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA 463 - Cabozantinib for previously treated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA 390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA 315: Canagliflozin in combination therapy for treating type 2 diabetes
Capecitabine 08.01.03 Formulary NICE TA 60 - Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine 08.01.03 Formulary NICE TA 100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Capecitabine 08.01.03 Formulary NICE TA 191 - Capecitabine for the treatment of advanced gastric cancer
Capsaicin 04.07.03 Formulary NICE clinical guideline 173 - Neuropathic pain in adults: pharmacological management in non-specialist settings
Carfilzomib 08.01.05 Formulary NICE TA 457 - Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA 121 - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib 08.01.05 Restricted Use NICE TA 395 - Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA 383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA 445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Restricted Use NICE TA 118 - Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Cetuximab 08.01.05 Restricted Use NICE TA 114 - Methadone and buprenorphine for the management of opioid dependence
Cetuximab 08.01.05 Restricted Use NICE TA 145 - Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab 08.01.05 Restricted Use NICE TA 439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (replaces NICE TA 176)
Ciclosporin 11.99.99.99 Formulary NICE TA 369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.01 Restricted Use NICE TA 117
Cinacalcet 09.05.01.02 Restricted Use NICE TA 117 - Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Colistimethate sodium nebuliser 05.01.07 Formulary NICE TA 276 - Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Crizotinib 08.01.05 Formulary NICE TA 422 - Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA 406 - Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dabigatran etexilate 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran etexilate 02.08.02 Formulary NICE TA 157 -Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran etexilate 02.08.02 Formulary NCIE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib 08.01.05 Formulary NICE TA 321 - Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA 396 - Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA 364 - Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Formulary NICE TA 441 - Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA 288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA 390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA 418 - Dapagliflozin in triple therapy for treating type 2 diabetes
Darbepoetin Alfa 09.01.03 Formulary NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Dasatinib 08.01.05 Formulary NICE TA 426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA 425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Degarelix 08.03.04.02 Formulary NICE TA 404 - Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab (metastases) 06.06.02 Formulary TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab (osteoporosis) 06.06.02 Formulary NICE TA 204 - Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TAG 229 - Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA 349 - Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA 320 - Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Docetaxel 08.01.05 Formulary NICE TA 109 - Docetaxel for the adjuvant treatment of early node-positive breast cancerBreast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA 101 - Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Donepezil 04.11 Formulary NICE TA 217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Duloxetine 04.07.03 Formulary NICE clinical guideline 173 - Neuropathic pain in adults: pharmacological management in non-specialist settings
Edoxaban 02.08.02 Formulary NICE TA 354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 02.08.02 Formulary NICE TA 355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Elbasvir & Grazoprevir. 05.03.01 Restricted Use NICE TA 413 - Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA 293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Empagliflozin 06.01.02.03 Formulary NICE TA 390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA - 336 - Empagliflozin in combination therapy for treating type 2 diabetes
Entecavir 05.03.03 Formulary NICE TA 153 - Entecavir for the treatment of chronic hepatitis B
Enzalutamide 08.01.05 Formulary NICE TA 377 - Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.01.05 Formulary NICE TA 316 - Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Formulary NICE TA 323 - Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Epoetin beta 09.01.03 Formulary NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Eribulin 08.01.05 Formulary NICE TA 423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA 258 - Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA 377 -Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Erlotinib 08.01.05 Formulary NICE TA 374 - Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA 227 - Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Etanercept 13.05.03 Formulary NICE TA 103 - Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 13.05.03 Formulary NICE TA 199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etanercept 13.05.03 Formulary NICE TA 455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Formulary NICE TA 195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA 383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA 373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etelcalcetide 09.05.01.02 Formulary NICE TA 448 - Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Restricted Use NICE TA 449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Restricted Use NICE TA 421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Restricted Use NICE TA 219 - Everolimus for the second-line treatment of advanced renal cell carcinoma
Everolimus 08.01.05 Restricted Use NICE TA 432 - Everolimus for advanced renal cell carcinoma after previous treatment
Evolocumab 02.14 Restricted Use NICE TA 394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Restricted Use NICE TA 421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Exenatide 06.01.02.03 Formulary NICE Guidelines - Type 2 diabetes in adults: management
Exenatide 06.01.02.03 Formulary NICE Guidelines - Type 2 diabetes in adults: management
Ezetimibe 02.12 Formulary NICE TA 385 - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA 164 - Febuxostat for the management of hyperuricaemia in people with gout
Finasteride 06.04.02 Formulary NICE CG 97 - Lower urinary tract symptoms in men: management
Fingolimod 08.02.04 Formulary NICE TA 254 - Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA 29 - Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine Phosphate 08.01.03 Formulary NICE TA 119 - Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fluocinolone intravitreal implant 11.04.01 Restricted Use NICE TA 301 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gabapentin 04.07.03 Formulary NICE clinical guideline 173 - Neuropathic pain in adults: pharmacological management in non-specialist settings
Galantamine 04.11 Formulary NICE TA 217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Galantamine 04.11 Formulary NICE TA 217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Galantamine 04.11 Formulary NICE TA 217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Gefitinib 08.01.05 Restricted Use NICE TA 192 - Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gemcitabine 08.01.03 Formulary NICE TA 25 - Guidance on the use of gemcitabine for the treatment of pancreatic cancer
Gemcitabine 08.01.03 Formulary NICE TA 116 - Gemcitabine for the treatment of metastatic breast cancer
Gemcitabine 08.01.03 Formulary NICE TA 389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Glatiramer Acetate 08.02.04 Formulary NICE TA 32 - Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA 383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA 220 - Golimumab for the treatment of psoriatic arthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Golimumab 13.05.03 Formulary NICE TA 220 - Golimumab for the treatment of psoriatic arthritis
Ibrutinib 08.01.05 Restricted Use NICE TA 429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Idelalisib 08.01.05 Formulary NICE TA 359 - Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 08.01.05 Formulary NICE TA 426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA 70 - Guidance on the use of imatinib for chronic myeloid leukaemia (partially replaced by TA 425/426)
Imatinib 08.01.05 Formulary NICE TA 425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA 326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Infliximab 10.01.03 Formulary NICE TA 383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA 195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 13.05.03 Formulary NICE TA 199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Infliximab 13.05.03 Formulary NICE TA 134 - Infliximab for the treatment of adults with psoriasis
Ipilimumab 08.01.05 Formulary NICE TA 268 - Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA 319 - Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan hydrochloride trihydrate (pegylated liposomal formulation) 08.01.05 Restricted Use NICE TA 440 - Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Ivabradine 02.05.05 Formulary NICE TA 267: Ivabradine for treating chronic heart failure
Ivabradine 02.06.03 Restricted Use CG 126: Management of Stable Angina
Ivabradine 02.06.03 Restricted Use NICE TA 267: Ivabradine for treating heart failure
Ixekizumab 13.05.03 Restricted Use NICE TA 442 - Ixekizumab for treating moderate to severe plaque psoriasis
Lapatinib 08.01.05 Formulary NICE TA 257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Ledipasvir & Sofosbuvir 05.03.03.02 Formulary NICE T A363 - Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA 171 - Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide 08.02.04 Formulary NICE TA 322 - Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Liraglutide 06.01.02.03 Formulary NICE Guideline - Type 2 diabetes in adults: management
Lubiprostone 01.02 Formulary NICE TA 318: Lubiprostone for treating chronic idiopathic constipation
Memantine 04.11 Formulary NICE TA 217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Methadone 04.07.02 Formulary NICE TA 114 - Methadone and buprenorphine for the management of opioid dependence
Methylprednisolone 06.03.02 Formulary NICE CG 186 - Multiple sclerosis in adults: management
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for treating symptoms of overactive bladder
Naftidrofuryl oxalate 02.06.04 Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Nalmefene 04.10.01 Formulary NICE TA 325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Restricted Use NICE TA 345 - Naloxegol for treating opioid‑induced constipation
Naltrexone Hydrochloride 04.10.03 Restricted Use NICE TA 115 - Naltrexone for the management of opioid dependence
Natalizumab 08.02.04 Formulary NICE TA 127 - Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
Necitumumab 08.01.05 Restricted Use NICE TA 411 - Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nilotinib 08.01.05 Formulary NICE TA 425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA 426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nintedanib 08.01.05 Formulary NICE TA 379 - Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Restricted Use NICE TA 347 - Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nivolumab 08.01.05 Restricted Use NICE TA 384 - Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.01.05 Restricted Use NICE TA 417 - Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.01.05 Restricted Use NICE TA 400 - Nivolumab in combination with ipilimumab for treating advanced melanoma
Obeticholic acid 01.09.01 Restricted Use NICE TA 443 - Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.01.05 Formulary NICE TA 343 - Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Ocriplasmin 0.5 mg/0.2mL 11.08.02 Formulary NICE TA 297 - Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.01.05 Formulary NICE TA 344 - Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Olaparib 08.01.05 Formulary NICE TA 381 - Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Omalizumab 03.04.02 Formulary NICE TA 339 - Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA 278 - Omalizumab for treating severe persistent allergic asthma
Ombitasvir + paritaprevir + Ritonavir 05.03.03.02 Formulary NICE TA 365 - Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA 158 - Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Oseltamivir 05.03.04 Formulary NICE TA 168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Osimertinib 08.01.05 Restricted Use NICE TA 416 - Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA 100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Paclitaxel 08.01.05 Formulary NICE TA 389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA 108 - Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Paclitaxel 08.01.05 Formulary NICE TA 55 - Guidance on the use of paclitaxel in the treatment of ovarian cancer
Panobinostat 08.01.05 Formulary NICE TA 380 - Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Restricted Use NICE TA 215 - Pazopanib for the first-line treatment of advanced renal cell carcinoma
Pegaptanib Sodium 11.08.02 Non Formulary NICE guidance on pegaptanib in AMD (August 2008)
Pegaspargase 08.01.05 Restricted Use NICE TA 408 - Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA 75 - Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 300 - Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon Alfa 08.02.04 Formulary NICE Clinical Guidelines 165 - Hepatitis B (chronic) : diagnosis and management
Peginterferon Alfa 08.02.04 Formulary NICE TA 96 - Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon Alfa 08.02.04 Formulary NICE TA 106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 300 - Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon Alfa 08.02.04 Formulary NICE Clinical Guidelines 165 - Hepatitis B (chronic) : diagnosis and management
Peginterferon Alfa 08.02.04 Formulary NICE TA 96 - Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon Alfa 08.02.04 Formulary NICE TA 75 - Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis
Peginterferon Alfa 08.02.04 Formulary NICE TA 200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA 75 -Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Beta 08.02.04 Formulary NICE TA 32 - Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
Pegylated Liposomal Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA 389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Pembrolizumab 08.01.05 Formulary NICE TA 447 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA 428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA 366 - Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA 357 - Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA 402 - Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA 190 - Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA 181 - Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA 124 - Pemetrexed for the treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA 135 - Pemetrexed for the treatment of malignant pleural mesothelioma
Pertuzumab 08.01.05 Formulary NICE TA 424 - Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone Capsules 03.11 Formulary NICE TA 282: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA 306 - Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA 427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA 451 - Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA 317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prasugrel 02.09 Formulary NICE TA182: Acute coronary syndrome - prasugrel
Pregabalin 04.07.03 Formulary NICE clinical guideline 173 - Neuropathic pain in adults: pharmacological management in non-specialist settings
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 08.01 Restricted Use NICE TA 412 - Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA 161 - Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Restricted Use NICE TA 403 - Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ramucirumab 08.01.05 Restricted Use NICE TA 378 - Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Ranibizumab 11.08.02 Formulary NICE TA 298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 11.08.02 Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA 283 - Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Formulary NICE TA274 - Ranibizumab for the treatment of diabetic macular oedema
Ranolazine 02.06.03 Formulary NICE CG 126: Managment of Stable Angina
Retigabine 04.08.01 Non Formulary NICE guidance, 2011
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Formulary NICE TA 106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Ribavirin 05.03.05 Formulary NICE TA 200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Ribavirin 05.03.05 Formulary NICE TA 75 - Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribavirin 05.03.05 Formulary NICE TA 300 - Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Rifaximin 05.01 Restricted Use NICE TA 337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Restricted Use NICE TA 20 - Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease
Risedronate 06.06.02 Formulary NICE TA 161 - Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Rituximab 08.02.03 Formulary NICE TA 243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab 08.02.03 Formulary NICE TA 308 - Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 08.02.03 Formulary NICE TA 226 - Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA 137: Lymphoma (follicular non-Hodgkins) - rituximab
Rituximab 08.02.03 Formulary NICE TA 174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Formulary NICE TA 193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab (rheumatology) 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in patients with AF
Rivaroxaban 02.08.02 Formulary NICE TA 287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA 170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 02.08.02 Formulary NICE TA 335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivastigmine 04.11 Formulary NICE TA 217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Non Formulary NICE Final Appraisal Determination Dec 2011
Romiplostim 09.01.04 Formulary NICE TA 221 - Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Ruxolitinib 08.01.05 Formulary NICE TA 386 - Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril / Valsartan 02.05.05.03 Restricted Use NICE TA 388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Secukinumab 10.01.03 Formulary NICE TA 445 -Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 10.01.03 Formulary NICE TA 350 - Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 10.01.03 Formulary NICE TA 407 - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Simeprevir 05.03.03.02 Formulary NICE TA 331 - Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sofosbuvir 05.03.03.02 Formulary NICE TA 330 - Sofosbuvir for treating chronic hepatitis C
Sofosbuvir + Velpatasvir 05.03.03.02 Formulary NICE TA 430 - Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Strontium Ranelate 06.06.02 Restricted Use NICE TA 161 - Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Sunitinib 08.01.05 Restricted Use NICE TA 449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Restricted Use NICE TA 169 - Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.05 Restricted Use NICE TA 179 - Sunitinib for the treatment of gastrointestinal stromal tumours
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Talimogene 08.02.04 Restricted Use NICE TA 410 - Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03 Formulary NICE TA 252 - Telaprevir for the treatment of genotype 1 chronic hepatitis C
Temozolomide 08.01.05 Formulary NICE TA 23 - Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide 08.01.05 Formulary NICE TA 121 - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Formulary NICE TA 173 - Tenofovir disoproxil for the treatment of chronic hepatitis B
Teriflunomide 08.02.04 Formulary NICE TA 303 - Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide 06.06.01 Formulary NICE TA 161 - Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Formulary NICE TA 228 - Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Formulary NICE TA 420 - Ticagrelor for preventing atherothrombotic events after myocardial infarction
Ticagrelor 02.09 Formulary NICE TAG 236: Ticagrelor for the treatment of acute coronary syndromes
Tobramycin 05.01.04 Formulary NICE TA 276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tocilizumab 10.01.03 Formulary NICE TA 373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA 238 - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Topotecan 08.01.05 Formulary NICE TA 183 - Topotecan for the treatment of recurrent and stage IVB cervical cancer
Topotecan 08.01.05 Formulary NICE TA 184 - Topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.05 Formulary NICE TA 91 : Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Topotecan 08.01.05 Formulary NICE TA 389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Formulary NICE TA 389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Formulary NICE TA 185 - Trabectedin for the treatment of advanced soft tissue sarcoma
Tramadol 04.07.02 Formulary NICE clinical guideline 173 - Neuropathic pain in adults: pharmacological management in non-specialist settings
Trametinib 08.01.05 Restricted Use NICE TA 396 - Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Formulary NICE TA 208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab 08.01.05 Formulary NICE TA 107 - Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Trastuzumab 08.01.05 Formulary NICE TA 34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trastuzumab 08.01.05 Formulary NICE TA 257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Trastuzumab emtansine 08.01.05 Formulary NICE TA 371 - Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
Trifluridine & Tipiracil 08.01.03 Restricted Use NICE TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 10.01.03 Formulary NICE TA 340 - Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary NICE TA 340 - Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary NICE TA 455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 13.05.03 Formulary NICE TA 180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 01.05.03 Formulary NICE TA 466 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Verteporfin 11.08.02 Formulary NICE TA 68 - Guidance on the use of photodynamic therapy for age-related macular degeneration
Vortioxetine 04.03 Formulary NICE TA 367 - Vortioxetine for treating major depressive episodes
Zolpidem 04.01.01 Restricted Use NICE TA 77 - Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA 77 - Zaleplon, zolpidem and zopiclone for the management of insomnia
Berkshire West NHS